The KEYNOTE-006 trial demonstrated a shorter OS in patients with the BRAF V600 mutation in the tumor, compared to patients without this mutation (median OS 13.9 vs. 28.1 months, HR = 0.73, p = 0.0048) [7]. Here, BRAF is linked to neoplasm.